Starting today, people with Parkinson's disease will have a new treatment option, thanks to U.S. Food and Drug Administration approval of groundbreaking new technology.
Among 13,711 matched pairs, GLP-1 receptor agonist users had a 10% lower risk for depression compared with DPP-4 inhibitor ...
The FDA approved the sale of Zyn nicotine pouches, which are increasingly popular with teens. But nicotine pouches cause ...
Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.
Groundbreaking research shows psilocybin therapy equals traditional antidepressants in treating depression with potential ...
Supernus' SPN-820 Phase 2b study in treatment-resistant depression failed to meet its primary endpoint, prompting further ...
The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...
A biotech company is attempting to persuade Kansas legislators to modify the state’s controlled substances act in advance of a possible new psychedelic treatment.
A pull-tab defect that might cause leakage and lead to botulism contamination is affecting some canned tuna products sold in ...
The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more ...
The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient clinic ...
The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient ...